<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373137</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00010818</org_study_id>
    <nct_id>NCT02373137</nct_id>
  </id_info>
  <brief_title>Descemet Endothelial Thickness Comparison Trial</brief_title>
  <acronym>DETECT</acronym>
  <official_title>Descemet Endothelial Thickness Comparison Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare visual acuity outcomes of two types of endothelial
      keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2)
      Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be
      randomized to have DSAEK and the other half will have DMEK.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corneal transplantation has evolved rapidly in recent years. Lamellar keratoplasty to replace
      diseased endothelium has led to faster recovery times, fewer complications, and better visual
      acuity outcomes. Currently, Descemet's Stripping Endothelial Keratoplasty (DSAEK) is the most
      common procedure because of its relative ease and good outcomes. Newer techniques such as
      Descemet's Membrane Endothelial Keratoplasty (DMEK), where Descemet's membrane alone is
      transplanted, has the potential to further improve visual acuity outcomes, produce fewer
      higher-order corneal aberrations and decrease rejection rates. However, donor preparation,
      increased intra-operative times, and problems with donor attachment in DMEK are all important
      limitations.

      There are three potential mechanisms by which DMEK may provide better visual acuity outcomes
      than DSAEK; graft thickness, interface haze and corneal higher-order aberrations. Graft
      thickness has been correlated with best spectacle corrected visual acuity (BSCVA) outcomes
      among thinner grafts. One retrospective case series found that 71% of thin endothelial grafts
      (defined as &lt;131μm) had BSCVA of 20/25 or better while only 50% of thick grafts (defined as
      ≥131) achieved this. In addition, higher-order aberrations, in particular of the posterior
      cornea, are increased after DSAEK. Theoretically, given the decreased tissue transplanted
      after DMEK this would be lessened, however, one retrospective series looking at higher order
      aberrations in DMEK compared with DSAEK found no difference in posterior aberrations of the
      central 4.0 mm zone between the two groups. Finally, interface haze may be increased in DSAEK
      and has been correlated with BSCVA.

      Ultrathin DSAEK involves donor preparation with a deep microkeratome pass to produce donor
      grafts less than 100 um thick. This procedure may have similar results to DMEK but without
      the technical difficulties. Several large prospective series show similar visual outcome
      results and rates of immunologic rejection between ultrathin DSAEK and DMEK, however
      comparisons are difficult. This comparative effectiveness clinical trial could directly
      address these important issues. The investigators also anticipate that secondary analyses of
      the trial data will allow us to address several more.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 22, 2015</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 4, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Spectacle-Corrected Visual Acuity</measure>
    <time_frame>6 months</time_frame>
    <description>The BSCVA was recorded at 4 meters by a masked refractionist certified for the study using a protocol adapted from the Age-Related Eye Disease Study using Early Treatment Diabetic Retinopathy Study charts: chart R(2110), chart 1(2111), and chart 2(2112) (Precision Vision, Woodstock, IL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Spectacle-Corrected Visual Acuity</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>The BSCVA was recorded at 4 meters by a masked refractionist certified for the study using a protocol adapted from the Age-Related Eye Disease Study using Early Treatment Diabetic Retinopathy Study charts: chart R(2110), chart 1(2111), and chart 2(2112) (Precision Vision, Woodstock, IL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Spectacle-Corrected Visual Acuity</measure>
    <time_frame>24 Months</time_frame>
    <description>The BSCVA was recorded at 4 meters by a masked refractionist certified for the study using a protocol adapted from the Age-Related Eye Disease Study using Early Treatment Diabetic Retinopathy Study charts: chart R(2110), chart 1(2111), and chart 2(2112) (Precision Vision, Woodstock, IL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Cell Count</measure>
    <time_frame>3, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Cell Count</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Higher-Order Aberrations</measure>
    <time_frame>3, 6, 12 months</time_frame>
    <description>Corneal anterior and posterior surface higher-order aberrations (HOA) were measured with Scheimpflug imaging (Pentacam) before surgery and at 3, 6, and 12 months post-operatively. Zernike orders 3-8 were calculated at 4.0- and 6.0-mm-diameter optical zones. The results reported here represent total HOA (Sum of Zernike orders 3-8). Note a single observation was not available for one eye in the DMEK group at 6 months, this was analyzed with last observation carried forward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Higher-Order Aberrations</measure>
    <time_frame>24 months</time_frame>
    <description>As measured by Pentacam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interface Haze</measure>
    <time_frame>3, 6, 12 months</time_frame>
    <description>As measured by Pentacam densitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interface Haze</measure>
    <time_frame>24 months</time_frame>
    <description>As measured by Pentacam densitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Eye Institute - Visual Functioning Questionnaire (NEI-VFQ)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>The National Eye Institute has developed the validated Visual Functioning Questionnaire (NEI-VFQ) to assess the effect of ocular conditions and vision on patient quality of life. The answers to the questionnaire are transformed into sub-scales, including: general health, general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision. Participants are assigned a numerical value for each sub-scale based on their answers between 0-100, where higher numbers indicate better visual function. These sub-scales are then combined according to National Eye Institute guidelines into an overall composite score for each participant. This overall composite score is also on a scale of 0-100, where higher numbers indicate better visual function.
Composite score based on National Eye Institute guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Failure/Graft Rejection</measure>
    <time_frame>Baseline 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Failure/Graft Rejection</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Refraction</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
    <description>Manifest refraction using phoropter</description>
  </other_outcome>
  <other_outcome>
    <measure>Graft Thickness</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
    <description>As measured by Optical coherence tomography (OCT) and Pachymetry</description>
  </other_outcome>
  <other_outcome>
    <measure>Operative Times</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events/Complication Rates</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
    <description>composite measure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Keratoplasty</condition>
  <condition>Grafting, Corneal</condition>
  <condition>Transplantation, Corneal</condition>
  <condition>Transplantation, Cornea</condition>
  <condition>Keratoplasty, Lamellar</condition>
  <arm_group>
    <arm_group_label>DSAEK</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMEK</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DSAEK</intervention_name>
    <arm_group_label>DSAEK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DMEK</intervention_name>
    <arm_group_label>DMEK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoserter</intervention_name>
    <description>The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.</description>
    <arm_group_label>DSAEK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone is a corticosteroid used to alleviate swelling post-surgery.</description>
    <arm_group_label>DMEK</arm_group_label>
    <arm_group_label>DSAEK</arm_group_label>
    <other_name>Millipred</other_name>
    <other_name>Orapred</other_name>
    <other_name>Omnipred</other_name>
    <other_name>Econopred</other_name>
    <other_name>Flo-Pred</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofloxacin</intervention_name>
    <description>Ofloxacin is an antibiotic used to treat bacterial infections of the eye.</description>
    <arm_group_label>DMEK</arm_group_label>
    <arm_group_label>DSAEK</arm_group_label>
    <other_name>Ocuflox</other_name>
    <other_name>Floxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tropicamide</intervention_name>
    <description>Tropicamide is a prescription drug used to dilate pupils during an eye exam.</description>
    <arm_group_label>DMEK</arm_group_label>
    <arm_group_label>DSAEK</arm_group_label>
    <other_name>Mydriacyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Phenylephrine is a prescription drug used to dilate pupils during an eye exam.</description>
    <arm_group_label>DMEK</arm_group_label>
    <arm_group_label>DSAEK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Jones Tube</intervention_name>
    <description>The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.</description>
    <arm_group_label>DMEK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Damaged or diseased endothelium from Fuchs or Pseudophakic Bullous Keratopathy

          -  Good candidates for corneal transplantation for either DMEK or DSAEK

          -  Willingness and ability to undergo a cornea transplantation

          -  Willingness to participate in follow-up visits

        Exclusion Criteria:

          -  Participants who are decisionally and/or cognitively impaired

          -  Participants who are not suitable for the DMEK or DSAEK surgeries

          -  Prior Endothelial Keratoplasty (EK) or any other ophthalmic surgery except
             uncomplicated cataract surgery

          -  Indication for surgery that is not suitable for EK (e.g. keratoconus, stromal
             dystrophies and scars)

          -  Presence of a condition that increases the probability for failure (e.g., heavily
             vascularized cornea, uncontrolled uveitis)

          -  Other primary endothelial dysfunction conditions including posterior polymorphous
             corneal dystrophy and congenital hereditary corneal dystrophy

          -  Aphakia, or anterior chamber intraocular lens (IOL) in study eye prior to or
             anticipated during EK

          -  Planned intraocular lens exchange of an anterior chamber IOL with a posterior chamber
             IOL in study at time of study EK

          -  Pre-operative central sub-epithelial or stromal scarring that the investigator
             believes is visually significant and could impact post-operative stromal clarity
             assessment

          -  Peripheral anterior synechiae (iris to angle) in the angle greater than a total of
             three clock hours

          -  Hypotony (Intraocular pressure &lt;10mmHg)

          -  Uncontrolled (defined as intraocular pressure &gt;25mmHg) glaucoma Visually significant
             optic nerve or macular pathology

          -  Visually significant optic nerve or macular pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winston Chamberlain, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Rose-Nussbaumer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Byers Eye Institute, Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>F. I. Proctor Foundation, University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute, Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Price FW Jr, Price MO. Evolution of endothelial keratoplasty. Cornea. 2013 Nov;32 Suppl 1:S28-32. doi: 10.1097/ICO.0b013e3182a0a307. Review.</citation>
    <PMID>24104929</PMID>
  </reference>
  <reference>
    <citation>Chen ES, Terry MA, Shamie N, Hoar KL, Friend DJ. Descemet-stripping automated endothelial keratoplasty: six-month results in a prospective study of 100 eyes. Cornea. 2008 Jun;27(5):514-20. doi: 10.1097/ICO.0b013e3181611c50.</citation>
    <PMID>18520497</PMID>
  </reference>
  <reference>
    <citation>Ham L, Dapena I, van Luijk C, van der Wees J, Melles GR. Descemet membrane endothelial keratoplasty (DMEK) for Fuchs endothelial dystrophy: review of the first 50 consecutive cases. Eye (Lond). 2009 Oct;23(10):1990-8. doi: 10.1038/eye.2008.393. Epub 2009 Jan 30.</citation>
    <PMID>19182768</PMID>
  </reference>
  <reference>
    <citation>Dirisamer M, van Dijk K, Dapena I, Ham L, Oganes O, Frank LE, Melles GR. Prevention and management of graft detachment in descemet membrane endothelial keratoplasty. Arch Ophthalmol. 2012 Mar;130(3):280-91. doi: 10.1001/archophthalmol.2011.343. Epub 2011 Nov 14.</citation>
    <PMID>22084160</PMID>
  </reference>
  <reference>
    <citation>Kruse FE, Laaser K, Cursiefen C, Heindl LM, Schlötzer-Schrehardt U, Riss S, Bachmann BO. A stepwise approach to donor preparation and insertion increases safety and outcome of Descemet membrane endothelial keratoplasty. Cornea. 2011 May;30(5):580-7.</citation>
    <PMID>21598430</PMID>
  </reference>
  <reference>
    <citation>Rudolph M, Laaser K, Bachmann BO, Cursiefen C, Epstein D, Kruse FE. Corneal higher-order aberrations after Descemet's membrane endothelial keratoplasty. Ophthalmology. 2012 Mar;119(3):528-35. doi: 10.1016/j.ophtha.2011.08.034. Epub 2011 Dec 22.</citation>
    <PMID>22197439</PMID>
  </reference>
  <reference>
    <citation>Busin M, Madi S, Santorum P, Scorcia V, Beltz J. Ultrathin descemet's stripping automated endothelial keratoplasty with the microkeratome double-pass technique: two-year outcomes. Ophthalmology. 2013 Jun;120(6):1186-94. doi: 10.1016/j.ophtha.2012.11.030. Epub 2013 Mar 1.</citation>
    <PMID>23466268</PMID>
  </reference>
  <reference>
    <citation>Guerra FP, Anshu A, Price MO, Giebel AW, Price FW. Descemet's membrane endothelial keratoplasty: prospective study of 1-year visual outcomes, graft survival, and endothelial cell loss. Ophthalmology. 2011 Dec;118(12):2368-73. doi: 10.1016/j.ophtha.2011.06.002. Epub 2011 Aug 27.</citation>
    <PMID>21872938</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <results_first_submitted>March 26, 2019</results_first_submitted>
  <results_first_submitted_qc>June 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Winston Chamberlain, MD, PhD</investigator_full_name>
    <investigator_title>Ophthalmologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Tropicamide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02373137/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02373137/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>UT-DSAEK</title>
          <description>Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
UT-DSAEK
Endoserter: The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.</description>
        </group>
        <group group_id="P2">
          <title>DMEK</title>
          <description>Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
DMEK
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
Jones Tube: The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3-Month Follow-Up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6-Month Follow-Up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12-Month Follow-Up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>UT-DSAEK</title>
          <description>Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
UT-DSAEK
Endoserter: The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.</description>
        </group>
        <group group_id="B2">
          <title>DMEK</title>
          <description>Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
DMEK
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
Jones Tube: The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>eyes</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="51" upper_limit="95"/>
                    <measurement group_id="B2" value="68" lower_limit="61" upper_limit="81"/>
                    <measurement group_id="B3" value="68" lower_limit="51" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>eyes</units>
          <param>Number</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Fuch's Dystrophy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pseudophakic Bullous Keratopathy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best Spectacle-Corrected Visual Acuity (logMAR)</title>
          <description>ETDRS Best spectacle-corrected visual acuity in logarithm of the minimum angle of resolution (logMAR) units</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.27" spread="0.21"/>
                    <measurement group_id="B2" value="0.34" spread="0.29"/>
                    <measurement group_id="B3" value="0.30" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgery</title>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Pseudophakic Endothelial Keratoplasty</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Triple Endothelial Keratoplasty</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="54" upper_limit="75"/>
                    <measurement group_id="B2" value="62" lower_limit="50" upper_limit="76"/>
                    <measurement group_id="B3" value="63" lower_limit="50" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Sex</title>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Death to Preservation Time</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" spread="4"/>
                    <measurement group_id="B2" value="9" spread="3"/>
                    <measurement group_id="B3" value="9" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Death to Surgery Time</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" spread="1"/>
                    <measurement group_id="B2" value="6" spread="1"/>
                    <measurement group_id="B3" value="6" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Endothelial Cell Count (pre-processing)</title>
          <units>cells/mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2792" spread="210"/>
                    <measurement group_id="B2" value="2797" spread="222"/>
                    <measurement group_id="B3" value="2795" spread="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Endothelial Cell Count (post-processing)</title>
          <units>cells/mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2796" spread="238"/>
                    <measurement group_id="B2" value="2771" spread="150"/>
                    <measurement group_id="B3" value="2783" spread="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Central Graft Thickness (UT-DSAEK only)</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" lower_limit="37" upper_limit="88"/>
                    <measurement group_id="B2" value="NA" lower_limit="NA" upper_limit="NA">N/A to DMEK grafts</measurement>
                    <measurement group_id="B3" value="73" lower_limit="37" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Corneal Thickness</title>
          <population>missing one value</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="18"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="37"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="24"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="610" spread="44"/>
                    <measurement group_id="B2" value="608" spread="52"/>
                    <measurement group_id="B3" value="609" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spherical Equivalent</title>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="19"/>
                <count group_id="B2" value="19"/>
                <count group_id="B3" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="25"/>
                <count group_id="B2" value="25"/>
                <count group_id="B3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.4" spread="1.9"/>
                    <measurement group_id="B2" value="-0.8" spread="2.2"/>
                    <measurement group_id="B3" value="-0.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Spectacle-Corrected Visual Acuity</title>
        <description>The BSCVA was recorded at 4 meters by a masked refractionist certified for the study using a protocol adapted from the Age-Related Eye Disease Study using Early Treatment Diabetic Retinopathy Study charts: chart R(2110), chart 1(2111), and chart 2(2112) (Precision Vision, Woodstock, IL).</description>
        <time_frame>6 months</time_frame>
        <population>One patient lost to followup</population>
        <group_list>
          <group group_id="O1">
            <title>UT-DSAEK</title>
            <description>Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
UT-DSAEK
Endoserter: The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.</description>
          </group>
          <group group_id="O2">
            <title>DMEK</title>
            <description>Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
DMEK
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
Jones Tube: The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Spectacle-Corrected Visual Acuity</title>
          <description>The BSCVA was recorded at 4 meters by a masked refractionist certified for the study using a protocol adapted from the Age-Related Eye Disease Study using Early Treatment Diabetic Retinopathy Study charts: chart R(2110), chart 1(2111), and chart 2(2112) (Precision Vision, Woodstock, IL).</description>
          <population>One patient lost to followup</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.16"/>
                    <measurement group_id="O2" value="0.05" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Linear</method>
            <method_desc>Multiple linear regression model with a covariate for baseline visual acuity.</method_desc>
            <param_type>Coefficient</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
            <estimate_desc>Coefficient reported in lines, comparing DMEK to UT-DSAEK. Compared to UT-DSAEK, DMEK had 1.8 lines better vision at 6 months.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Spectacle-Corrected Visual Acuity</title>
        <description>The BSCVA was recorded at 4 meters by a masked refractionist certified for the study using a protocol adapted from the Age-Related Eye Disease Study using Early Treatment Diabetic Retinopathy Study charts: chart R(2110), chart 1(2111), and chart 2(2112) (Precision Vision, Woodstock, IL).</description>
        <time_frame>3 and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>UT-DSAEK</title>
            <description>Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
UT-DSAEK
Endoserter: The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.</description>
          </group>
          <group group_id="O2">
            <title>DMEK</title>
            <description>Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
DMEK
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
Jones Tube: The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Spectacle-Corrected Visual Acuity</title>
          <description>The BSCVA was recorded at 4 meters by a masked refractionist certified for the study using a protocol adapted from the Age-Related Eye Disease Study using Early Treatment Diabetic Retinopathy Study charts: chart R(2110), chart 1(2111), and chart 2(2112) (Precision Vision, Woodstock, IL).</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.21"/>
                    <measurement group_id="O2" value="0.11" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.18"/>
                    <measurement group_id="O2" value="0.04" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of 3-Month Visual Acuity Between Groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Regression, Linear</method>
            <method_desc>Multiple linear regression model with a covariate for baseline visual acuity</method_desc>
            <param_type>Coefficient</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
            <estimate_desc>Coefficient reported in lines, comparing DMEK to UT-DSAEK. Compared to UT-DSAEK, DMEK had 1.5 lines better vision at 3 months.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of 12 Month Visual Acuity Between Groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Linear</method>
            <method_desc>Multiple linear regression model with a covariate for baseline visual acuity</method_desc>
            <param_type>Coefficient</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
            <estimate_desc>Coefficient reported in lines, comparing DMEK to UT-DSAEK. Compared to UT-DSAEK, DMEK had 1.4 lines better vision at 12 months.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Spectacle-Corrected Visual Acuity</title>
        <description>The BSCVA was recorded at 4 meters by a masked refractionist certified for the study using a protocol adapted from the Age-Related Eye Disease Study using Early Treatment Diabetic Retinopathy Study charts: chart R(2110), chart 1(2111), and chart 2(2112) (Precision Vision, Woodstock, IL).</description>
        <time_frame>24 Months</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelial Cell Count</title>
        <time_frame>3, 6, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>UT-DSAEK</title>
            <description>Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
UT-DSAEK
Endoserter: The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.</description>
          </group>
          <group group_id="O2">
            <title>DMEK</title>
            <description>Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
DMEK
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
Jones Tube: The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Cell Count</title>
          <units>cells/mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2114" spread="357"/>
                    <measurement group_id="O2" value="2037" spread="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2113" spread="301"/>
                    <measurement group_id="O2" value="1963" spread="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2070" spread="292"/>
                    <measurement group_id="O2" value="1855" spread="448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Coefficient</param_type>
            <param_value>-77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-326</ci_lower_limit>
            <ci_upper_limit>172</ci_upper_limit>
            <estimate_desc>Comparing DMEK to UT-DSAEK at 3 months.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Coefficient</param_type>
            <param_value>-150</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-356</ci_lower_limit>
            <ci_upper_limit>66</ci_upper_limit>
            <estimate_desc>Comparing DMEK to UT-DSAEK at 6 months.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.051</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Coefficient</param_type>
            <param_value>-215</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-430</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
            <estimate_desc>Comparing DMEK to UT-DSAEK at 12 months.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelial Cell Count</title>
        <time_frame>24 months</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Higher-Order Aberrations</title>
        <description>Corneal anterior and posterior surface higher-order aberrations (HOA) were measured with Scheimpflug imaging (Pentacam) before surgery and at 3, 6, and 12 months post-operatively. Zernike orders 3-8 were calculated at 4.0- and 6.0-mm-diameter optical zones. The results reported here represent total HOA (Sum of Zernike orders 3-8). Note a single observation was not available for one eye in the DMEK group at 6 months, this was analyzed with last observation carried forward.</description>
        <time_frame>3, 6, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>UT-DSAEK</title>
            <description>Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
UT-DSAEK
Endoserter: The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.</description>
          </group>
          <group group_id="O2">
            <title>DMEK</title>
            <description>Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
DMEK
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
Jones Tube: The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Higher-Order Aberrations</title>
          <description>Corneal anterior and posterior surface higher-order aberrations (HOA) were measured with Scheimpflug imaging (Pentacam) before surgery and at 3, 6, and 12 months post-operatively. Zernike orders 3-8 were calculated at 4.0- and 6.0-mm-diameter optical zones. The results reported here represent total HOA (Sum of Zernike orders 3-8). Note a single observation was not available for one eye in the DMEK group at 6 months, this was analyzed with last observation carried forward.</description>
          <units>root mean square in micrometers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months Anterior Cornea 4.0-mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.274" spread="0.223"/>
                    <measurement group_id="O2" value="0.288" spread="0.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months Posterior Cornea 4.0-mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.217" spread="0.110"/>
                    <measurement group_id="O2" value="0.116" spread="0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months Anterior Cornea 6.0-mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.897" spread="0.800"/>
                    <measurement group_id="O2" value="0.829" spread="0.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months Posterior Cornea 6.0-mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.621" spread="0.308"/>
                    <measurement group_id="O2" value="0.346" spread="0.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months Anterior Cornea 4.0-mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.230" spread="0.110"/>
                    <measurement group_id="O2" value="0.243" spread="0.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months Posterior Cornea 4.0-mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.179" spread="0.067"/>
                    <measurement group_id="O2" value="0.095" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months Anterior Cornea 6.0-mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.739" spread="0.371"/>
                    <measurement group_id="O2" value="0.724" spread="0.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months Posterior Cornea 6.0-mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.505" spread="0.217"/>
                    <measurement group_id="O2" value="0.288" spread="0.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months Anterior Cornea 4.0-mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.228" spread="0.108"/>
                    <measurement group_id="O2" value="0.241" spread="0.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months Posterior Cornea 4.0-mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.159" spread="0.068"/>
                    <measurement group_id="O2" value="0.098" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months Anterior Cornea 6.0-mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.725" spread="0.344"/>
                    <measurement group_id="O2" value="0.723" spread="0.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months Posterior Cornea 6.0-mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.459" spread="0.206"/>
                    <measurement group_id="O2" value="0.284" spread="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Higher-Order Aberrations</title>
        <description>As measured by Pentacam</description>
        <time_frame>24 months</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interface Haze</title>
        <description>As measured by Pentacam densitometry</description>
        <time_frame>3, 6, 12 months</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interface Haze</title>
        <description>As measured by Pentacam densitometry</description>
        <time_frame>24 months</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>National Eye Institute - Visual Functioning Questionnaire (NEI-VFQ)</title>
        <description>The National Eye Institute has developed the validated Visual Functioning Questionnaire (NEI-VFQ) to assess the effect of ocular conditions and vision on patient quality of life. The answers to the questionnaire are transformed into sub-scales, including: general health, general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision. Participants are assigned a numerical value for each sub-scale based on their answers between 0-100, where higher numbers indicate better visual function. These sub-scales are then combined according to National Eye Institute guidelines into an overall composite score for each participant. This overall composite score is also on a scale of 0-100, where higher numbers indicate better visual function.
Composite score based on National Eye Institute guidelines.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>For this analysis, all &quot;second eyes&quot; (enrolled eyes belonging to a patient that had enrolled their other eye and already had surgery on that eye as part of this study) were removed. For this reason the total number of eyes equals the total number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>UT-DSAEK</title>
            <description>Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
UT-DSAEK
Endoserter: The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.</description>
          </group>
          <group group_id="O2">
            <title>DMEK</title>
            <description>Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
DMEK
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
Jones Tube: The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>National Eye Institute - Visual Functioning Questionnaire (NEI-VFQ)</title>
          <description>The National Eye Institute has developed the validated Visual Functioning Questionnaire (NEI-VFQ) to assess the effect of ocular conditions and vision on patient quality of life. The answers to the questionnaire are transformed into sub-scales, including: general health, general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision. Participants are assigned a numerical value for each sub-scale based on their answers between 0-100, where higher numbers indicate better visual function. These sub-scales are then combined according to National Eye Institute guidelines into an overall composite score for each participant. This overall composite score is also on a scale of 0-100, where higher numbers indicate better visual function.
Composite score based on National Eye Institute guidelines.</description>
          <population>For this analysis, all &quot;second eyes&quot; (enrolled eyes belonging to a patient that had enrolled their other eye and already had surgery on that eye as part of this study) were removed. For this reason the total number of eyes equals the total number of participants.</population>
          <units>Composite scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>eyes</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="13.4"/>
                    <measurement group_id="O2" value="72.3" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>eyes</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9" spread="9.1"/>
                    <measurement group_id="O2" value="87.3" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Failure/Graft Rejection</title>
        <time_frame>Baseline 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>UT-DSAEK</title>
            <description>Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
UT-DSAEK
Endoserter: The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.</description>
          </group>
          <group group_id="O2">
            <title>DMEK</title>
            <description>Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
DMEK
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
Jones Tube: The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Failure/Graft Rejection</title>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Graft Rejection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Failure/Graft Rejection</title>
        <time_frame>Baseline to 24 months</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Refraction</title>
        <description>Manifest refraction using phoropter</description>
        <time_frame>3, 6, 12, 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Graft Thickness</title>
        <description>As measured by Optical coherence tomography (OCT) and Pachymetry</description>
        <time_frame>3, 6, 12, 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Operative Times</title>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Events/Complication Rates</title>
        <description>composite measure</description>
        <time_frame>3, 6, 12, 24 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>Adverse events are reported by eye (N = 50), not by participant (N = 38).</desc>
      <group_list>
        <group group_id="E1">
          <title>UT-DSAEK</title>
          <description>Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
UT-DSAEK
Endoserter: The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.</description>
        </group>
        <group group_id="E2">
          <title>DMEK</title>
          <description>Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
DMEK
Prednisolone: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Ofloxacin: Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
Tropicamide: Tropicamide is a prescription drug used to dilate pupils during an eye exam.
Phenylephrine: Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
Jones Tube: The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma (nonsurgical)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Glaucoma (surgical)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Graft displacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Graft failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Graft rejection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infectious keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Posterior synechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Re-bubble</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Visually significant central epithelial opacity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Intralocular lens repositioning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Epiretinal membrane and lamellar hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cystoid macular edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Postoperative day 1 pupillary block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jennifer Rose-Nussbaumer</name_or_title>
      <organization>Kaiser Permanente / University of California, San Francisco</organization>
      <phone>650-299-2111</phone>
      <email>Jennifer.Rose-Nussbaumer@kp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

